ArriVent BioPharma, Inc.
AVBPUnited States
10 filed reports · 182 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
10 reports · Mar 2024 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 8 | 1,014 | Mar 2024 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 2 | 630 | Dec 2024 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 12, 2026 | 255 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 11, 2026 | 144 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Mar 5, 2026 | 387 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 10, 2025 | 156 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 11, 2025 | 93 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 12, 2025 | 95 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Mar 3, 2025 | 243 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 14, 2024 | 95 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 14, 2024 | 83 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 8, 2024 | 93 | Open |
Financial data
182 concepts · 1,644 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial175 concepts · 1,526 facts · Dec 2022 to Jun 2026
- Research and development28 · Dec 2023 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value17 · Mar 2023 to Jun 2026
- Allocated share based compensation expense17 · Mar 2023 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents17 · Mar 2023 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect17 · Mar 2023 to Jun 2026
- General and administrative expense (US GAAP)17 · Mar 2023 to Jun 2026
- Increase decrease in accounts payable trade17 · Mar 2023 to Jun 2026
- Increase decrease in accrued liabilities17 · Mar 2023 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets17 · Mar 2023 to Jun 2026
- Net cash provided by used in financing activities17 · Mar 2023 to Jun 2026
- Net cash provided by used in operating activities17 · Mar 2023 to Jun 2026
- Net income loss17 · Mar 2023 to Jun 2026
- Net income loss available to common stockholders basic17 · Mar 2023 to Jun 2026
- Net income loss available to common stockholders diluted17 · Mar 2023 to Jun 2026
- Operating expenses (US GAAP)17 · Mar 2023 to Jun 2026
- Operating income loss17 · Mar 2023 to Jun 2026
- Proceeds from stock options exercised17 · Mar 2023 to Jun 2026
- Profit loss17 · Mar 2023 to Jun 2026
- Research and development expense17 · Mar 2023 to Jun 2026
- Share based compensation17 · Mar 2023 to Jun 2026
- Stockholders equity (US GAAP)17 · Mar 2023 to Jun 2026
- Stock issued during period value stock options exercised17 · Mar 2023 to Jun 2026
- Accounts payable current14 · Dec 2023 to Jun 2026
- Accrued liabilities current14 · Dec 2023 to Jun 2026
Segment7 concepts · 118 facts · Dec 2023 to Jun 2026
- Further40 · Dec 2023 to Jun 2026
- Firmonertinib13 · Dec 2023 to Jun 2026
- Life science13 · Dec 2023 to Jun 2026
- Net income loss13 · Dec 2023 to Jun 2026
- Other general and administrative expense13 · Dec 2023 to Jun 2026
- Research and development expense13 · Dec 2023 to Jun 2026
- Segment reporting other item amount13 · Dec 2023 to Jun 2026
Segments
118 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments1 member · 118 facts
- Single Reportable118 · Dec 2023 to Jun 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.